scispace - formally typeset
C

Carlos Flores

Researcher at University of La Laguna

Publications -  87
Citations -  1954

Carlos Flores is an academic researcher from University of La Laguna. The author has contributed to research in topics: Population & Genome-wide association study. The author has an hindex of 25, co-authored 85 publications receiving 1487 citations. Previous affiliations of Carlos Flores include Carlos III Health Institute.

Papers
More filters
Journal ArticleDOI

Genome-wide association and HLA fine-mapping studies identify risk loci and genetic pathways underlying allergic rhinitis

Johannes Waage, +104 more
- 16 Jul 2018 - 
TL;DR: In this article, the authors carried out a meta-analysis of allergic rhinitis in 59,762 cases and 152,358 controls of European ancestry and identified a total of 41 risk loci.
Journal ArticleDOI

Tachykinins and tachykinin receptors in human uterus

TL;DR: Analysis of the expression of preprotachykinins, tachykinin receptors and the cell‐surface peptidase, neprilysin, in the myometrium from pregnant and nonpregnant women is consistent with a role of tachy Kinins in the regulation of human uterine function.
Journal ArticleDOI

A predominant European ancestry of paternal lineages from Canary Islanders.

TL;DR: The results indicate that, contrary to mtDNA data, paternal lineages of the current population are overwhelmingly of European origin, arguing for a highly asymmetric pattern of mating after European occupation.
Journal ArticleDOI

Nanopore sequencing and its application to the study of microbial communities.

TL;DR: In this paper, an up-to-date summary of the experimental protocols and bioinformatic tools for the study of microbial communities using nanopore sequencing, highlighting the most important and recent research in the field with a major focus on infectious diseases.
Posted ContentDOI

precisionFDA Truth Challenge V2: Calling variants from short- and long-reads in difficult-to-map regions

Nathan D. Olson, +75 more
- 15 Nov 2020 - 
TL;DR: The precisionFDA Truth Challenge V2 aimed to assess the state-of-the-art of variant calling in difficult-to-map regions and the Major Histocompatibility Complex and new methods out-performed the 2016 Truth Challenge winners.